

1 **Multi-steroid profiling by uPLC-MS/MS with post-column infusion of ammonium**  
2 **fluoride**

3 Lina Schiffer<sup>1</sup>, Fozia Shaheen<sup>1</sup>, Lorna C. Gilligan<sup>1</sup>, Karl-Heinz Storbeck<sup>1,2</sup>, James Hawley<sup>3</sup>,  
4 Brian G. Keevil<sup>3</sup>, Wiebke Art<sup>1,4</sup>, Angela E. Taylor<sup>1</sup>

5 <sup>1</sup> Institute of Metabolism and Systems Research (IMSR), University of Birmingham,  
6 Birmingham, UK

7 <sup>2</sup> Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa

8 <sup>3</sup> Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester NHS Foundation  
9 Trust, Manchester, UK

10 **Corresponding author:** Dr Angela E Taylor, Institute of Metabolism and Systems  
11 Research, University of Birmingham, Birmingham B15 2TT, UK. E-mail:  
12 [a.taylor.5@bham.ac.uk](mailto:a.taylor.5@bham.ac.uk)

13 **Abstract**

14 **Background:** Multi-steroid profiling is a powerful analytical tool that simultaneously  
15 quantifies steroids from different biosynthetic pathways. Here we present an ultra-high  
16 performance liquid chromatography-tandem mass spectrometry (uPLC-MS/MS) assay for  
17 the profiling of 25 steroids using post-column infusion of ammonium fluoride.

18 **Methods:** Following liquid-liquid extraction, steroids were chromatographically separated  
19 over 5 minutes using a Phenomenex Luna Omega C<sub>18</sub> column and a water (0.1 % formic  
20 acid) methanol gradient. Quantification was performed on a Waters Acquity uPLC and Xevo<sup>®</sup>  
21 TQ-XS mass spectrometer. Ammonium fluoride (6 mmol/L, post-column infusion) and formic  
22 acid (0.1 % (vol/vol), mobile phase additive) were compared as additives to aid ionisation.

23 **Results:** Post-column infusion (PCI) of ammonium fluoride (NH<sub>4</sub>F) enhanced ionisation in a  
24 steroid structure-dependent fashion compared to formic acid (122-140% for 3βOH-Δ5  
25 steroids and 477-1274% for 3-keto-Δ4 steroids). Therefore, we fully analytically validated  
26 PCI with NH<sub>4</sub>F. Lower limits of quantification ranged from 0.28 to 3.42 nmol/L; 23 of 25  
27 analytes were quantifiable with acceptable accuracy (bias range -14% to 11.9%). Average  
28 recovery ranged from 91.6% to 113.6% and average matrix effects from -29.9% to 19.9%.  
29 Imprecision ranged from 2.3% to 23.9% for all analytes and was <15% for 18/25 analytes.  
30 The serum multi-steroid profile of 10 healthy men and 10 healthy women was measured.

31 **Conclusions:** uPLC-MS/MS with post-column infusion of ammonium fluoride enables  
32 comprehensive multi-steroid profiling through enhanced ionisation particularly benefiting the  
33 detection of 3-keto-Δ4 steroids.

34 **Key words:** steroid quantification, 11-oxygenated androgens, liquid chromatography-  
35 tandem mass spectrometry, androgens, mineralocorticoids, glucocorticoids.

36

37 **Highlights (3-5; 85 max. characters)**

38

39

40 • This multi-steroid profiling assay quantifies 25 steroids in 5.5 minutes

41

42 • Post-column infusion of  $\text{NH}_4\text{F}$  enhances the ionisation of 3-keto- $\Delta^4$  steroids

43

44 • The assay simultaneously quantifies steroids from several biosynthetic pathways

45

46 • We present analytical data validated for serum steroid profiling

47

48

49

50

## 51 **1. Introduction**

52 Steroid hormones are biosynthesised in the adrenal cortex and gonads via cascade-like,  
53 interlinked enzymatic pathways and undergo extensive metabolism with both activation and  
54 inactivation in peripheral tissues (Figure 1) leading to a complex circulating steroid  
55 metabolome [1]. Steroid flux through the different pathways can be severely dysregulated in  
56 various conditions, requiring comprehensive steroid assessment to develop a mechanistic  
57 understanding of the condition and for diagnosis and treatment monitoring. Disorders of  
58 steroidogenesis with distinct steroid metabolome profiles include inborn enzymatic  
59 deficiencies such as congenital adrenal hyperplasia, autonomous adrenal steroid production  
60 such as Cushing syndrome or primary aldosteronism [2], adrenocortical carcinoma [3, 4],  
61 polycystic ovary syndrome and idiopathic intracranial hypertension [5-7]. Steroid-dependent  
62 cancers, such as prostate cancer, can locally activate steroids and are treated with various  
63 pharmacological or surgical approaches to deplete the relevant steroids and their precursors  
64 in circulation [8].

65 Traditionally, individual steroids have been used for the assessment of a suspected  
66 underlying condition (e.g. testosterone (T) for female androgen excess [9]; 17 $\alpha$ -  
67 hydroxyprogesterone (17OHP) for congenital adrenal hyperplasia [10]). Mechanistic in-vitro  
68 studies often rely on the measurement of the end products of a biosynthesis pathway only.  
69 However, the determination of a multi-steroid profile has several advantages over the use of  
70 selected individual markers. First, steroid precursor/product ratios can be calculated to  
71 identify distinct effects on individual enzymes [11] and to assess the degree of steroid  
72 precursor activation in conditions of steroid excess. For example, in serum the ratio of T to  
73 its less active precursor androstenedione (A4) and the ratio of T to the more potent  
74 androgen 5 $\alpha$ -dihydrotestosterone (DHT) have been shown to be excellent markers for  
75 androgen excess and the associated adverse metabolic phenotype in polycystic ovary  
76 syndrome [5, 12, 13]. Secondly, multi-steroid profiling enables different pathways of  
77 steroidogenesis to be assessed simultaneously, which is essential due to the interlinked  
78 nature of steroidogenesis and the contribution of individual enzymes to several pathways  
79 (Figure 1). Thirdly, multi-steroid profiling can be used to investigate off-target effects of  
80 inhibitors of steroidogenesis. Finally, multi-steroid profiling can be combined with machine  
81 learning approaches to generate powerful, unbiased and automated diagnostic steroid  
82 metabolomics tools [3, 4].

83 In contrast to immunoassays, mass spectrometry allows for multiplexing of analytes and  
84 liquid chromatography for the high-throughput that is required to effectively use multi-steroid  
85 profiling in clinical and research laboratories. Steroid analysis by mass spectrometry is often  
86 limited by poor sensitivity due to low analyte concentrations in biological samples and low  
87 ionisation efficiency of the analytes. Mobile phase additives can improve the

88 chromatography (peak separation and shape), enhance the signal and, thereby, sensitivity.  
89 Formic (methanoic) acid and acetic acid are common additives for corticosteroids and  
90 androgen analysis in the positive ionisation mode [5, 14, 15] as they can promote the  
91 formation of protonated molecular ions (M+H)<sup>+</sup>. Ammonium fluoride (NH<sub>4</sub>F) can aid the  
92 ionisation of steroids in electrospray ionisation (ESI) in negative mode [16] and hence  
93 improve the sensitivity of oestrogen measurements [17, 18]. Additionally, NH<sub>4</sub>F has been  
94 reported to augment the ionisation of steroids using ESI in positive ion mode in a structure-  
95 dependent manner, when coupled to supercritical fluid chromatography [19]. Here, we  
96 present an ultra-high performance liquid chromatography-tandem mass spectrometry (uPLC-  
97 MS/MS) assay to measure 25 steroids (Table 1) from the mineralocorticoid, glucocorticoid,  
98 androgen, alternative and 11-oxygenated steroidogenic pathways. The separation was  
99 achieved in 5 minutes using post-column infusion of NH<sub>4</sub>F in positive ionisation mode to  
100 enhance ionisation.

101

## 102 **2. Material and methods**

### 103 **2.1 Preparation of external standards and quality controls**

104 Pure standards of all analytes were purchased as powders from Sigma-Aldrich (Gillingham,  
105 UK) and Steraloids (Newport, USA); for details see Supplemental Table 1. The purity of all  
106 standards was confirmed by gas chromatography-mass spectrometry. Individual stock  
107 solutions at 1 mg/mL were prepared in uPLC grade methanol (Biosolve, Dieuze, France) and  
108 stored at -80 °C. Using the stock solutions, combined calibrators for all analytes were  
109 prepared by spiking phosphate buffered saline (PBS) pH 7.4 supplemented with 0.1%  
110 (wt/vol) bovine serum albumin (BSA) (Sigma-Aldrich) yielding at least 10 different final  
111 concentrations from 0 up to 250 ng/mL (Supplemental Table 2). A combined internal  
112 standard stock solution containing 0.5 µg/mL of each internal standard was prepared in  
113 deuterated methanol (Sigma-Aldrich).

114 Quality control (QC) samples were prepared by spiking PBS 0.1% BSA from independent 1  
115 mg/mL stock solutions. Four different concentrations covering the expected concentration  
116 range human serum (Supplemental Table 2). Additionally, pooled human serum (Sigma-  
117 Aldrich) was aliquoted, stored at -80 °C and used as biological QC in each analytical run. All  
118 calibrators, internal standards and QCs were stored at -20 °C.

### 119 **2.2 Collection of serum samples**

120 The collection of blood samples was approved by the authors' Institutional Review Board  
121 (Science, Technology, Engineering and Mathematics Ethical Review Committee of the  
122 University of Birmingham, ERN\_17-0494). Informed, written consent was obtained from all  
123 individuals included in this study. Following venous puncture, blood was collected into gold

124 top SST Vacutainers<sup>®</sup> (Becton, Dickinson, Wokingham, UK). Samples were spun and the  
125 serum removed and stored at -80 °C until analysis. The method was applied to 20 serum  
126 samples from healthy volunteers 10 female and 10 males (20-40 years).

### 127 **2.3 Sample preparation**

128 Steroids were extracted by liquid-liquid extraction. A set of calibrators, QCs and biological  
129 QCs were prepared with each batch of samples. Sample, calibrator, or QC (200 µL) were  
130 transferred into a hexamethyldisilazane-treated glass tube and 10 µL of the internal standard  
131 mixture containing all stable isotope labelled internal standards listed in Table S1. 50 µL of  
132 acetonitrile (Biosolve, Dieuze, FR) was added to precipitate the proteins and the samples  
133 were vortexed. 1-mL of tert-butyl methyl ether (Acros Organics, Fisher Scientific UK Ltd,  
134 Loughborough, UK) was added to each sample and the samples were vortexed at 1000 rpm  
135 for 10 minutes on a multi-vortex. The samples were incubated at room temperature for at  
136 least 30 minutes to aid phase separation. The organic phase was subsequently transferred  
137 into the wells of a 2-mL square well 96-well plate (Porvair Sciences Ltd, Wrexham, UK)  
138 containing 700 µL glass inserts (Randox, Crumlin, UK) and dried under a nitrogen stream at  
139 45 °C. The dried extract was reconstituted in 100 µL of 50% (vol/vol) uPLC grade methanol  
140 (Biosolve) in uPLC grade water (Biosolve) prior to analysis.

### 141 **2.4 Ultra-high performance liquid chromatography**

142 Chromatography was performed on an Acquity ultra performance liquid chromatography  
143 system (uPLC; Waters Ltd, Wilmslow, UK) using a Phenomenex Luna Omega column, 1.6  
144 µm, polar C18, 100 Å, 2.1 x 50 mm; (Phenomenex, Macclesfield, UK) at 60 °C. 10 µL of the  
145 reconstituted sample was injected. Mobile phase A consisted of uPLC grade water  
146 (Biosolve) and mobile phase B of uPLC grade methanol (Biosolve). An optimised method  
147 with a linear gradient from 45% to 75% of mobile phase B was applied over five minutes at a  
148 flow rate of 0.6 mL/min to separate the analytes followed by a 98% wash and equilibration at  
149 starting conditions prior to the injection of the next sample. The auto sampler was  
150 maintained at 10 °C. To investigate ionisation 0.1% (vol/vol) formic acid (added to mobile  
151 phase A or both A and B) was compared to PCI of NH<sub>4</sub>F.

### 152 **2.5 Tandem mass spectrometry**

153 The uPLC eluate was injected into a XEVO<sup>®</sup> TQ-XS mass spectrometer (Waters Ltd) using  
154 ESI in positive ion mode. Post-column infusion 6 mmol/L NH<sub>4</sub>F in 50% (vol/vol) was  
155 combined using the fluidics system on the mass spectrometer under full software control.  
156 The capillary voltage was maintained at 1.5 kV, the source temperature was 150 °C,  
157 desolvation temperature and gas flow were 600 °C and 1200 L/h, cone gas was 150 L/h.  
158 MassLynx 4.2 software (Waters Ltd) was used for systems control. Qualifier and quantifier  
159 mass transitions, cone voltages and collision energies are summarised in Table 2.

160 TargetLynx software was used for data processing and quantification. Peak area ratios of  
161 analyte to internal standard were plotted against the nominal concentrations of the  
162 calibrators and 1/x weighting and linear least square regression were used to produce the  
163 standard curve.

## 164 **2.6 Validation**

165 Validation was performed following protocols from published guidelines [20-22]. For each  
166 steroid, validation has been performed at different concentrations representing low, medium  
167 and high concentrations of that steroid in serum. While this method has utility for many  
168 applications, we opted to validate for a serum application. We selected serum because it is a  
169 complex mixture of steroids, proteins, salts and many other constituents. These constituents  
170 can vary between individuals and can each affect steroid extraction and ionisation  
171 efficiencies. In addition, serum contains steroids at a range of concentrations, for example  
172 low level poor ionising steroids such as DHT (<0.3 ng/mL (1 nM)) and high concentration  
173 good ionisers like cortisol (~18 to 300 ng/mL (50-800 nM)). Optimisation using such a  
174 complex matrix means adaptation of this method to other 'cleaner' bio-fluids or cell culture  
175 supernatants should be simple.

### 176 **2.6.1 Recovery and matrix effects**

177 Matrix effects and recovery were determined as previously described [23, 24]. Six different  
178 human serum samples (four male and two female) were spiked at 5 ng/mL before extraction  
179 (pre-extract) and after extraction and reconstitution (post extract). Additionally, the  
180 reconstitution solvent (50% (vol/vol) uPLC grade methanol in uPLC grade water) was spiked  
181 with the same amounts of analytes (no extract). Percentage matrix effects and recovery  
182 were calculated from the concentrations quantified in the samples:

183

*Matrix Effects (%)*

$$= \frac{\text{Concentration (post extract)} - \text{Concentration (no extract)}}{\text{Concentration (no extract)}} \times 100$$

184

$$\text{Recovery (\%)} = \frac{\text{Concentration (pre extract)}}{\text{Concentration (post extract)}} \times 100$$

185

186 For matrix effects mean values between -15 and 15% were considered ideal and -20% and  
187 20% were acceptable. For recovery mean values between 80% and 120% were defined  
188 acceptable.

### 189 **2.6.2 Linearity**

190 Three calibration series were prepared by different scientists. For each analyte the ratio of  
191 analyte peak area to internal standard peak area was plotted against the nominal

192 concentrations of the standard as described above. Calibration curves were accepted as  
193 linear if the correlation coefficient of the linear regression ( $R^2$ ) was  $\geq 0.99$ .

### 194 **2.6.3 Lower limit of quantification**

195 The lower limit of quantification (LLOQ) was defined as the lowest concentration for which 10  
196 replicate samples of spiked surrogate matrix could be run with a CV  $< 20\%$  and a bias not  
197 greater than  $\pm 20\%$ .

### 198 **2.6.4 Imprecision**

199 Pooled surrogate matrix samples spiked with all analytes at four different concentrations  
200 (0.3, 1, 3 and 30 ng/mL) were run 10 times in the same batch to assess intra-assay  
201 imprecision. Pooled serum samples and pooled serum samples spiked with 5 ng/mL for all  
202 analytes were also run 10 times in the same batch to assess intra-assay imprecision. These  
203 samples were extracted and run in different batches to assess inter-assay imprecision ( $n$   
204  $= 20$ ). A CV  $\leq 15\%$  was considered optimal.

### 205 **2.6.5 Accuracy**

206 10 samples of surrogate matrix were spiked individually at four different concentrations (0.3,  
207 1, 3 and 30 ng/mL). A bias of the observed concentration and the nominal concentration  
208 between  $-15\%$  and  $+15\%$  was considered optimal.

209

## 210 **3. Results**

### 211 **3.1 Chromatographic separation**

212 Analytes were separated using a linear gradient over five minutes followed by 0.5 minutes at  
213 starting conditions for equilibration resulting in a total run time injection-to-injection of 5.5  
214 minutes. All analytes eluted as distinct, identifiable peaks (Supplemental Figure 1). Two  
215 pairs of analytes co-eluted: (cortisol ( $m/z$  363) and 11KA4 ( $m/z$  301); 17OHP ( $m/z$  330) and  
216 17Preg ( $m/z$  332)). No interference was observed due to the differences in  $m/z$  (Table 2).

### 217 **3.2 Comparison of additives to improve ionisation**

218 The effect of  $\text{NH}_4\text{F}$  on signal intensity was assessed in comparison to our previously  
219 published method using 0.1% (vol/vol) formic acid as mobile phase additive in both the  
220 methanol and water phases [5, 7]. We chose to add  $\text{NH}_4\text{F}$  by post-column infusion as  
221 preliminary experiments with  $\text{NH}_4\text{F}$  as an additive led to increases in system pressure  
222 indicative of damage to the column material (data not shown). The intra-assay imprecision  
223 using this modification was acceptable with a mean CV of the peak area of 7.0% for all  
224 analytes (CV range 3.9 to 13.7%;  $n=60$  injections of the same sample (data not shown)).  
225 Peak areas of all analytes in serum ( $n=73$ ) were compared between the assay with formic  
226 acid in both mobile phases and the assay using post-column infusion of  $\text{NH}_4\text{F}$ .  $\text{NH}_4\text{F}$

227 increased peak area in a structure-dependent fashion (Figure 2, Supplemental Figure 2). In  
228 comparison to formic acid, NH<sub>4</sub>F induced significant increases in the peak area of steroids  
229 with 3-keto- $\Delta^4$  structure (Prog, DOC, B, Aldo, 17OHP, S, E, F, A4, 11OHA4, 11KA4, T,  
230 11KT, 11OHT), with mean increases varying from 477% (17OHP) to 1274% (Aldo). NH<sub>4</sub>F  
231 had a lower impact on the peak area of the majority of A-ring reduced steroids with changes  
232 varying between 100% and 381% (DHT, 5 $\alpha$ -dione, 3 $\alpha$ -diol, An, 5 $\alpha$ -DHP, 3 $\alpha$ 5 $\alpha$ 17HP), with  
233 the exceptions of alloP (841%) and 17OHDHP (1280%). NH<sub>4</sub>F post-column infusion had  
234 only a very minor impact on the peak areas of 3 $\beta$ -OH- $\Delta^5$  steroids (Preg, 17Preg, DHEA).  
235 Our final optimised method employed 6 mmol/L NH<sub>4</sub>F introduced via post-column infusion at  
236 a flow rate of 5  $\mu$ L/min, with 0.1% (vol/vol) formic acid in the water mobile phase to limit the  
237 risk of microbial contamination.

### 238 **3.3 Validation of the analytical performance**

239 The analytical performance of the optimised assay with post-column infusion of NH<sub>4</sub>F and  
240 0.1% (vol/vol) formic acid in mobile phase A was validated. Matrix effects and recovery were  
241 assessed for six different serum samples (Table 3). Mean matrix effects ranged from -19.5%  
242 to 19.9% for all analytes and were hence in the desired range from -20% to 20%, except for  
243 5 $\alpha$ DHP (-29.9%), 17OHDHP (-22.6%) and 3 $\alpha$ 5 $\alpha$ 17HP (-62.7%). Mean recovery ranged from  
244 90.0% to 113.6% for all analytes except for 3 $\alpha$ 5 $\alpha$ 17HP (122.1%), which was just outside the  
245 acceptance range of 80-120%. Calibration curves were linear with an R<sup>2</sup>  $\geq$ 0.99 for all  
246 analytes (Supplemental Table 2). Lower limits of quantification ranged between 0.1 ng/mL  
247 (~0.3 nmol/L) and 0.5 ng/mL (~1.5 nmol/L) for all analytes except for 17Preg and 3 $\alpha$ -adiol,  
248 which had a limit of quantification of 1 ng/mL (corresponding to 3.01 and 3.42 nmol/L,  
249 respectively) (Table 3). The accuracy (bias) and imprecision of the assay were assessed  
250 with spiked PBS 0.1% BSA samples at four different concentrations. The bias between the  
251 observed and nominal concentrations was calculated as a measure of accuracy and the  
252 coefficient of variation (CV) as a measure of imprecision (Table 4). Bias was within  
253 acceptable limits for the majority of analytes at all concentrations above the LLOQ ranging  
254 from -14.0 to 11.9%, with the exception of 5 $\alpha$ DHP at 0.3 ng/mL (-21%) and 17OHPreg at 1  
255 ng/mL (-17.0%). Imprecision was within acceptable limits for the majority of analytes at  
256 concentrations above the LLOQ ranging from 2.3 to 14.7% with the exception of An (15.2%  
257 at 0.3 ng/mL), 3 $\alpha$ -adiol (17.8% at 1 ng/mL), 17OHPreg (16.5% at 3 ng/mL) and alloP (at all  
258 concentrations imprecision ranged from 15.1 to 20.5%).

259 Additionally, imprecision was assessed using a pooled serum sample (Table 5). The levels  
260 in this pooled serum sample were below the limit of quantification for 11 analytes (Preg,  
261 Prog, Aldo, DOC, 5 $\alpha$ -dione, 3 $\alpha$ -adiol, An, 5 $\alpha$ DHP, alloP, 17OHDHP, 3 $\alpha$ 5 $\alpha$ 17HP). For the  
262 remaining analytes the intra-assay CV ranged from 2.4 to 16.3% and the inter-assay CV



263 from 3.5 to 16.1%. For a pooled serum sample spiked with 5 ng/mL of all analytes the intra-  
264 assay CV was between 2.3% and 12.5% for all analytes. The inter-assay CV was <15% (3.2  
265 to 14.7%) for all steroids except 17OHDHP (17.2%), 3 $\alpha$ -adiol (23.0%), 5 $\alpha$ -DHP (22%) and  
266 3 $\alpha$ 5 $\alpha$ 17HP (23.9%).

267

268

### 269 **3.4 Serum steroid profiling in healthy volunteers**

270 Following validation, we applied this assay to the measurement of serum samples from 10  
271 female (aged 23-39 years) and 10 male healthy volunteers (aged 28-37 years). The highest  
272 concentrations were observed for glucocorticoids (F and E), the adrenal androgen precursor  
273 DHEA and the mineralocorticoid precursor B. As expected, men had higher levels of T and  
274 DHT than women and the levels of all other adrenal derived steroids were similar in men and  
275 women (Figure 3). Concentrations of progesterone and its metabolites 5 $\alpha$ DHP and alloP  
276 were below the LLOQ in men and in 8 of 10 women. 17OHDHP was not detected in any of  
277 the samples (Figure 3). The levels of 17Preg quantified in the samples using our assay were  
278 notably higher than expected based on our previous reference ranges and publications by  
279 other laboratories. While our validation demonstrates that 17Preg can be measured with  
280 acceptable precision (Table 4, 5), we conclude that using the assay presented here 17Preg  
281 cannot be quantified accurately in serum.

282

## 283 **4. Discussion**

284 Multi-steroid profiling provides a wider insight than quantification of a single steroid marker.  
285 A multiplexed approach has extensive utility for the diagnosis, monitoring and the  
286 development of a mechanistic understanding of steroid-associated conditions as it allows for  
287 the integration of steroid flux across all pathways of steroid biosynthesis and metabolism [2,  
288 25]. This has led several clinical laboratories to increase the number of analytes that are  
289 multiplexed in a single assay [14, 26-28]. Here, we describe the development and validation  
290 of an uPLC-MS/MS assay for the simultaneous measurement of 25 steroids from the  
291 mineralocorticoid, glucocorticoid, and androgen pathways of steroid biosynthesis with a total  
292 run-time of 5.5 minutes.

293 Formic acid is a standard mobile phase additive for the analysis of steroids in positive  
294 ionisation mode as 3-keto- $\Delta$ 4 steroids predominantly form protonated molecular ions [M+H]<sup>+</sup>.  
295 However, the sensitivity achieved with formic acid as an additive can still be insufficient to  
296 accurately quantify the low levels of certain steroids present in serum. Hence, we tested the  
297 effect of post-column infusion of NH<sub>4</sub>F on the signal of all 25 steroids in our assay and  
298 established large increases in peak area for all 3-keto- $\Delta$ 4 analytes in the presence of NH<sub>4</sub>F

299 compared to formic acid, with lower impact observed on the ionisation of A-ring reduced and  
300  $3\beta\text{OH-}\Delta 5$  steroids. These findings are consistent with published results on the effect of  $\text{NH}_4\text{F}$   
301 on the ionisation of selected steroids in a supercritical fluid chromatography set up with ESI  
302 in positive mode [19]. 3-keto- $\Delta 4$  steroids predominantly form quasi molecular ions  $[\text{M}+\text{H}]^+$   
303 during ESI. Parr et al. [19] speculate that the signal enhancement observed for 3-keto- $\Delta 4$  is  
304 due to the formation of  $[\text{M}+\text{H}]^+$  ions being aided in the presence of  $\text{NH}_4\text{F}$ , as the proton  
305 affinity of 3-keto- $\Delta 4$  steroids is higher than that of ammonia. Another possible mechanism is  
306 that  $\text{F}^-$  ions capture potential  $\text{Na}^+$  contaminations in the mobile phases, hence preventing the  
307 formation of  $[\text{M}+\text{Na}]^+$  adducts.

308 While other assays for steroid analysis by ESI in positive mode use  $\text{NH}_4\text{F}$  as mobile phase  
309 additives [18, 29], we chose to supply  $\text{NH}_4\text{F}$  by post-column infusion to allow for cost- and  
310 time efficient incorporation of the assay into lab workflows. As indicated by the system  
311 pressure increased in our own preliminary experiments with  $\text{NH}_4\text{F}$  in the mobile phase,  $\text{NH}_4\text{F}$   
312 can have detrimental effects on column lifetime [30], which is circumvented by post-column  
313 infusion. If running different assays on the same LC-MS/MS system, post-column infusion of  
314 additives limits the variability of mobile phase compositions that are used on the system,  
315 which could reduce the time needed for equilibration, when switching between assays that  
316 require different additives. The use of the in-built fluidics system of the mass spectrometer  
317 for the post-column infusion is simple, robust, and fully automated.

318 The analytical validation of the assay revealed that 23/25 of the analytes can be robustly  
319 quantified at typical serum concentrations, while one of the intermediates of the alternative  
320 DHT biosynthesis pathway (3 $\alpha$ 5 $\alpha$ 17HP) and the precursor steroid 17Preg can only be semi-  
321 quantitatively profiled, although the clinical utility of these steroids has yet to be determined.  
322 We applied the assay to serum samples from healthy male and female volunteers thereby  
323 demonstrating the utility of the assay.

324 To the best of our knowledge, only two LC-MS/MS assays, which analyse 20 or more  
325 steroids in serum or plasma, have been published to date [31, 32]. However, the run-times of  
326 these assays (16 minutes [31] and 8 minutes [32]) are significantly longer than that of our  
327 assay. Published assays with run-times <6 minutes cover a maximum of 16 analytes [33-36].  
328 Additionally, while other assays focus mainly on adrenal steroids [28, 33, 37-39] or androgen  
329 panels [14, 40], our assay comprehensively covers multiple steroid classes (Figure 1). In  
330 addition to classic androgens, such as A4 and T, our assay covers the alternative pathway of  
331 DHT biosynthesis, which contributes to androgen excess in CAH [41, 42], and the 11-  
332 oxygenated androgens, which have only recently been shown to have major relevance for  
333 the diagnosis and mechanistic understanding of androgen excess conditions [6, 43-45].

334 Here we explored the application of this method to interrogate the complex matrix of serum.  
335 With minimal adaptations this uPLC-MS/MS method can be applied to other matrices such

336 as bio-fluids (saliva, follicular fluid, micro-dialysis fluid etc.), tissues (adipose, brain, prostate  
337 etc.), and *in-vitro* cell/organ culture experiments. These applications would need further  
338 validation to determine extraction recovery and matrix effects, but depending on the matrix  
339 they could conceivably provide improved accuracy and precision especially at the LLOQ.  
340 Our assay has limitations that might be considered to hamper its use in routine clinical  
341 laboratories: It uses liquid-liquid extraction, which is inexpensive, but time-consuming and  
342 labour-intense, when performed manually, and can be challenging to automate. However,  
343 the assay can be adjusted for an extraction technique with higher throughput and better  
344 potential for (semi-)automation like supported liquid extraction or C<sub>18</sub> solid phase extraction,  
345 used with satisfying results by other serum multi-steroid assays [14, 28, 39]. Moreover, post-  
346 column infusion as a mode of additive delivery is not available on all mass spectrometers,  
347 where this is the case external pumps can be purchased to enable post-column infusion.  
348 Finally, not all analytes in our assay have their own stable isotope-labelled internal standard,  
349 which is usually considered a prerequisite to appropriately control for matrix effects and  
350 extraction losses and to allow for accurate and precise quantification [27, 46]. At the time this  
351 assay was developed, no internal standards were commercially available for 5 $\alpha$ -dione,  
352 11OHT, 5 $\alpha$ DHP, 17OHDHP or 3 $\alpha$ 5 $\alpha$ 17HP. Therefore, quantification was performed using  
353 the internal standard eluting closest to the analyte, our validation data proves this approach  
354 to be sufficient. Use of customised deuterium- or <sup>13</sup>C-labelled internal standards is expensive  
355 but could improve accuracy and imprecision of these analytes.

356

## 357 **7. Conclusions**

358  $\mu$ PLC-MS/MS with post-column infusion of ammonium fluoride enables the high throughput,  
359 sensitive profiling of 25 steroids. Use of NH<sub>4</sub>F significantly increased sensitivity for most  
360 steroids. The method was analytically validated and applied to human serum.

361

362 **Acknowledgments:** The authors thank the volunteers for the donation of blood samples.

363 **Research funding:** Wellcome Trust (Investigator Award WT209492/Z/17/Z, to W.A.)

364 Academy of Medical Sciences UK (Newton Advanced Fellowship NAF004\1002, to K.H.S).

365

366

## 367 References

- 368 [1] L. Schiffer, L. Barnard, E.S. Baranowski, L.C. Gilligan, A.E. Taylor, W. Arlt, C.H.L.  
369 Shackleton, K.H. Storbeck, Human steroid biosynthesis, metabolism and excretion are  
370 differentially reflected by serum and urine steroid metabolomes: A comprehensive review,  
371 *The Journal of steroid biochemistry and molecular biology*, 194 (2019) 105439.
- 372 [2] K.H. Storbeck, L. Schiffer, E.S. Baranowski, V. Chortis, A. Prete, L. Barnard, L.C.  
373 Gilligan, A.E. Taylor, J. Idkowiak, W. Arlt, C.H.L. Shackleton, Steroid Metabolome Analysis  
374 in Disorders of Adrenal Steroid Biosynthesis and Metabolism, *Endocrine reviews*, 40 (2019)  
375 1605-1625.
- 376 [3] W. Arlt, M. Biehl, A.E. Taylor, S. Hahner, R. Libe, B.A. Hughes, P. Schneider, D.J. Smith,  
377 H. Stiekema, N. Krone, E. Porfiri, G. Opocher, J. Bertherat, F. Mantero, B. Allolio, M.  
378 Terzolo, P. Nightingale, C.H. Shackleton, X. Bertagna, M. Fassnacht, P.M. Stewart, Urine  
379 steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, *The*  
380 *Journal of clinical endocrinology and metabolism*, 96 (2011) 3775-3784.
- 381 [4] I. Bancos, A.E. Taylor, V. Chortis, A.J. Sitch, C. Jenkinson, C.J. Davidge-Pitts, K. Lang,  
382 S. Tsagarakis, M. Macech, A. Riester, T. Deutschbein, I.D. Pupovac, T. Kienitz, A. Prete,  
383 T.G. Papathomas, L.C. Gilligan, C. Bancos, G. Reimondo, M. Haissaguerre, L. Marina, M.A.  
384 Grytaas, A. Sajwani, K. Langton, H.E. Ivison, C.H.L. Shackleton, D. Erickson, M. Asia, S.  
385 Palimeri, A. Kondracka, A. Spyroglou, C.L. Ronchi, B. Simunov, D.A. Delivanis, R.P.  
386 Sutcliffe, I. Tsiros, T. Bednarczyk, M. Reincke, S. Burger-Stritt, R.A. Felders, L. Canu, H.R.  
387 Haak, G. Eisenhofer, M.C. Denny, G.A. Ueland, M. Ivovic, A. Tabarin, M. Terzolo, M.  
388 Quinkler, D. Kastelan, M. Fassnacht, F. Beuschlein, U. Ambroziak, D.A. Vassiliadi, M.W.  
389 O'Reilly, W.F. Young, Jr., M. Biehl, J.J. Deeks, W. Arlt, Urine steroid metabolomics for the  
390 differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test  
391 validation study, *Lancet Diabetes Endocrinol*, 8 (2020) 773-781.
- 392 [5] M.W. O'Reilly, A.E. Taylor, N.J. Crabtree, B.A. Hughes, F. Capper, R.K. Crowley, P.M.  
393 Stewart, J.W. Tomlinson, W. Arlt, Hyperandrogenemia predicts metabolic phenotype in  
394 polycystic ovary syndrome: the utility of serum androstenedione, *The Journal of clinical*  
395 *endocrinology and metabolism*, 99 (2014) 1027-1036.
- 396 [6] M.W. O'Reilly, P. Kempegowda, C. Jenkinson, A.E. Taylor, J.L. Quanson, K.H. Storbeck,  
397 W. Arlt, 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary  
398 Syndrome, *The Journal of clinical endocrinology and metabolism*, 102 (2017) 840-848.
- 399 [7] M.W. O'Reilly, C.S. Westgate, C. Hornby, H. Botfield, A.E. Taylor, K. Markey, J.L.  
400 Mitchell, W.J. Scotton, S.P. Mollan, A. Yiangou, C. Jenkinson, L.C. Gilligan, M. Sherlock, J.  
401 Gibney, J.W. Tomlinson, G.G. Lavery, D.J. Hodson, W. Arlt, A.J. Sinclair, A unique androgen  
402 excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid  
403 dynamics, *JCI insight*, 4 (2019).
- 404 [8] G. Snaterse, J.A. Visser, W. Arlt, J. Hofland, Circulating steroid hormone variations  
405 throughout different stages of prostate cancer, *Endocrine-related cancer*, 24 (2017) R403-  
406 r420.
- 407 [9] D. Lizneva, L. Gavrilova-Jordan, W. Walker, R. Azziz, Androgen excess: Investigations  
408 and management, *Best practice & research. Clinical obstetrics & gynaecology*, 37 (2016) 98-  
409 118.
- 410 [10] J.W. Honour, 17-Hydroxyprogesterone in children, adolescents and adults, *Annals of*  
411 *clinical biochemistry*, 51 (2014) 424-440.
- 412 [11] M.P. Caulfield, T. Lynn, M.E. Gottschalk, K.L. Jones, N.F. Taylor, E.M. Malunowicz,  
413 C.H. Shackleton, R.E. Reitz, D.A. Fisher, The diagnosis of congenital adrenal hyperplasia in  
414 the newborn by gas chromatography/mass spectrometry analysis of random urine  
415 specimens, *The Journal of clinical endocrinology and metabolism*, 87 (2002) 3682-3690.
- 416 [12] J. Munzker, D. Hofer, C. Trummer, M. Ulbing, A. Harger, T. Pieber, L. Owen, B. Keevil,  
417 G. Brabant, E. Lerchbaum, B. Obermayer-Pietsch, Testosterone to dihydrotestosterone ratio  
418 as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome,  
419 *The Journal of clinical endocrinology and metabolism*, 100 (2015) 653-660.

- 420 [13] J. Munzker, L. Lindheim, J. Adaway, C. Trummer, E. Lerchbaum, T.R. Pieber, B. Keevil,  
421 B. Obermayer-Pietsch, High salivary testosterone-to-androstenedione ratio and adverse  
422 metabolic phenotypes in women with polycystic ovary syndrome, *Clinical endocrinology*, 86  
423 (2017) 567-575.
- 424 [14] J.M. Hawley, J.E. Adaway, L.J. Owen, B.G. Keevil, Development of a total serum  
425 testosterone, androstenedione, 17-hydroxyprogesterone, 11beta-hydroxyandrostenedione  
426 and 11-ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical  
427 sample stability, *Clinical chemistry and laboratory medicine*, DOI 10.1515/cclm-2019-  
428 0959(2020).
- 429 [15] Y.-C. Ma, H.-Y. Kim, Determination of Steroids by Liquid Chromatography/Mass  
430 Spectrometry, *Journal of the American Society for Mass Spectrometry*, 8 (1997) 1010-1020.
- 431 [16] N.S. Rannulu, R.B. Cole, Novel Fragmentation Pathways of Anionic Adducts of Steroids  
432 Formed by Electrospray Anion Attachment Involving Regioselective Attachment,  
433 Regiospecific Decompositions, Charge-Induced Pathways, and Ion–Dipole Complex  
434 Intermediates, *Journal of the American Society for Mass Spectrometry*, 23 (2012) 1558-  
435 1568.
- 436 [17] L.J. Owen, F.C. Wu, B.G. Keevil, A rapid direct assay for the routine measurement of  
437 oestradiol and oestrone by liquid chromatography tandem mass spectrometry, *Annals of*  
438 *clinical biochemistry*, 51 (2014) 360-367.
- 439 [18] S.W. Blue, A.J. Winchell, A.V. Kaucher, R.A. Lieberman, C.T. Gilles, M.N. Pyra, R.  
440 Heffron, X. Hou, R.W. Coombs, K. Nanda, N.L. Davis, A.P. Kourtis, J.T. Herbeck, J.M.  
441 Baeten, J.R. Lingappa, D.W. Erikson, Simultaneous quantitation of multiple contraceptive  
442 hormones in human serum by LC-MS/MS, *Contraception*, 97 (2018) 363-369.
- 443 [19] M.K. Parr, B. Wüst, J. Teubel, J.F. Joseph, Splitless hyphenation of SFC with MS by  
444 APCI, APPI, and ESI exemplified by steroids as model compounds, *Journal of*  
445 *Chromatography B*, 1091 (2018) 67-78.
- 446 [20] J.W. Honour, Development and validation of a quantitative assay based on tandem  
447 mass spectrometry, *Annals of clinical biochemistry*, 48 (2011) 97-111.
- 448 [21] U.S. Department of Health and Human Services Food and Drug Administration  
449 Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for  
450 Industry, DOI (2018).
- 451 [22] B.J. Linnert K, Selection and analytical evaluation of methods – with statistical  
452 techniques., in: A.E. Burtis CA, Bruns DE (Ed.) *Tietz textbook of clinical chemistry and*  
453 *molecular diagnostics*, Saunders, St. Louis, 2006, pp. 353-407.
- 454 [23] P.J. Taylor, Matrix effects: the Achilles heel of quantitative high-performance liquid  
455 chromatography-electrospray-tandem mass spectrometry, *Clinical biochemistry*, 38 (2005)  
456 328-334.
- 457 [24] T.M. Annesley, Ion suppression in mass spectrometry, *Clinical chemistry*, 49 (2003)  
458 1041-1044.
- 459 [25] C. Shackleton, O.J. Pozo, J. Marcos, GC/MS in Recent Years Has Defined the Normal  
460 and Clinically Disordered Steroidome: Will It Soon Be Surpassed by LC/Tandem MS in This  
461 Role?, *Journal of the Endocrine Society*, 2 (2018) 974-996.
- 462 [26] N. Janzen, S. Sander, M. Terhardt, M. Peter, J. Sander, Fast and direct quantification of  
463 adrenal steroids by tandem mass spectrometry in serum and dried blood spots, *Journal of*  
464 *Chromatography B*, 861 (2008) 117-122.
- 465 [27] B.G. Keevil, Novel liquid chromatography tandem mass spectrometry (LC-MS/MS)  
466 methods for measuring steroids, *Best practice & research. Clinical endocrinology &*  
467 *metabolism*, 27 (2013) 663-674.
- 468 [28] S. Schweitzer, M. Kunz, M. Kurlbaum, J. Vey, S. Kendl, T. Deutschbein, S. Hahner, M.  
469 Fassnacht, T. Dandekar, M. Kroiss, Plasma steroid metabolome profiling for the diagnosis of  
470 adrenocortical carcinoma, *European journal of endocrinology*, 180 (2019) 117-125.
- 471 [29] C. Wright, P. O'Day, M. Alyamani, N. Sharifi, R.J. Auchus, Abiraterone acetate  
472 treatment lowers 11-oxygenated androgens, *European journal of endocrinology*, 182 (2020)  
473 413-421.

- 474 [30] J.J. Pesek, M.T. Matyska, Ammonium fluoride as a mobile phase additive in aqueous  
475 normal phase chromatography, *Journal of chromatography. A*, 1401 (2015) 69-74.
- 476 [31] M.R. Hakkinen, T. Murtola, R. Voutilainen, M. Poutanen, T. Linnanen, J. Koskivuori, T.  
477 Lakka, J. Jaaskelainen, S. Auriola, Simultaneous analysis by LC-MS/MS of 22 ketosteroids  
478 with hydroxylamine derivatization and underivatized estradiol from human plasma, serum  
479 and prostate tissue, *Journal of pharmaceutical and biomedical analysis*, 164 (2019) 642-652.
- 480 [32] Z. Wang, H. Wang, Y. Peng, F. Chen, L. Zhao, X. Li, J. Qin, Q. Li, B. Wang, B. Pan, W.  
481 Guo, A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to  
482 profile 20 plasma steroids in endocrine disorders, *Clinical chemistry and laboratory*  
483 *medicine*, DOI 10.1515/cclm-2019-0869(2020).
- 484 [33] G. Karvaly, K. Kovacs, K. Meszaros, I. Kocsis, A. Patocs, B. Vasarhelyi, The  
485 comprehensive characterization of adrenocortical steroidogenesis using two-dimensional  
486 ultra-performance liquid chromatography - electrospray ionization tandem mass  
487 spectrometry, *Journal of pharmaceutical and biomedical analysis*, 153 (2018) 274-283.
- 488 [34] U. Ceglarek, L. Kortz, A. Leichtle, G.M. Fiedler, J. Kratzsch, J. Thiery, Rapid  
489 quantification of steroid patterns in human serum by on-line solid phase extraction combined  
490 with liquid chromatography-triple quadrupole linear ion trap mass spectrometry, *Clinica*  
491 *chimica acta; international journal of clinical chemistry*, 401 (2009) 114-118.
- 492 [35] A. Gaudl, J. Kratzsch, Y.J. Bae, W. Kiess, J. Thiery, U. Ceglarek, Liquid  
493 chromatography quadrupole linear ion trap mass spectrometry for quantitative steroid  
494 hormone analysis in plasma, urine, saliva and hair, *Journal of chromatography. A*, 1464  
495 (2016) 64-71.
- 496 [36] S. Matysik, G. Liebisch, Quantification of steroid hormones in human serum by liquid  
497 chromatography-high resolution tandem mass spectrometry, *Journal of chromatography. A*,  
498 1526 (2017) 112-118.
- 499 [37] D.R. Taylor, L. Ghataore, L. Couchman, R.P. Vincent, B. Whitelaw, D. Lewis, S. Diaz-  
500 Cano, G. Galata, K.M. Schulte, S. Aylwin, N.F. Taylor, A 13-Steroid Serum Panel Based on  
501 LC-MS/MS: Use in Detection of Adrenocortical Carcinoma, *Clinical chemistry*, 63 (2017)  
502 1836-1846.
- 503 [38] A.S. Boggs, J.A. Bowden, T.M. Galligan, L.J. Guillette, Jr., J.R. Kucklick, Development  
504 of a multi-class steroid hormone screening method using Liquid Chromatography/Tandem  
505 Mass Spectrometry (LC-MS/MS), *Analytical and bioanalytical chemistry*, 408 (2016) 4179-  
506 4190.
- 507 [39] M. Peitzsch, T. Dekkers, M. Haase, F.C. Sweep, I. Quack, G. Antoch, G. Siegert, J.W.  
508 Lenders, J. Deinum, H.S. Willenberg, G. Eisenhofer, An LC-MS/MS method for steroid  
509 profiling during adrenal venous sampling for investigation of primary aldosteronism, *The*  
510 *Journal of steroid biochemistry and molecular biology*, 145 (2015) 75-84.
- 511 [40] L.J. Owen, F.C. Wu, R.M. Buttler, B.G. Keevil, A direct assay for the routine  
512 measurement of testosterone, androstenedione, dihydrotestosterone and  
513 dehydroepiandrosterone by liquid chromatography tandem mass spectrometry, *Annals of*  
514 *clinical biochemistry*, 53 (2016) 580-587.
- 515 [41] C. Kamrath, Z. Hochberg, M.F. Hartmann, T. Remer, S.A. Wudy, Increased activation of  
516 the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency: evidence from  
517 urinary steroid hormone analysis, *The Journal of clinical endocrinology and metabolism*, 97  
518 (2012) E367-375.
- 519 [42] N. Reisch, A.E. Taylor, E.F. Nogueira, D.J. Asby, V. Dhir, A. Berry, N. Krone, R.J.  
520 Auchus, C.H.L. Shackleton, N.A. Hanley, W. Arlt, Alternative pathway androgen biosynthesis  
521 and human fetal female virilization, *Proc Natl Acad Sci U S A*, 116 (2019) 22294-22299.
- 522 [43] A.F. Turcu, A.T. Nanba, R. Chomic, S.K. Upadhyay, T.J. Giordano, J.J. Shields, D.P.  
523 Merke, W.E. Rainey, R.J. Auchus, Adrenal-derived 11-oxygenated 19-carbon steroids are  
524 the dominant androgens in classic 21-hydroxylase deficiency, *European journal of*  
525 *endocrinology*, 174 (2016) 601-609.
- 526 [44] I. Bacila, J. Adaway, J. Hawley, S. Mahdi, R. Krone, L. Patel, S. Alvi, T. Randell, E.  
527 Gevers, M. Dattani, T. Cheetham, A. Kyriakou, L. Schiffer, F. Ryan, E. Crowne, J.H. Davies,  
528 S.F. Ahmed, B. Keevil, N. Krone, Measurement of Salivary Adrenal-Specific Androgens as

529 Biomarkers of Therapy Control in 21-Hydroxylase Deficiency, The Journal of clinical  
530 endocrinology and metabolism, 104 (2019) 6417-6429.  
531 [45] C. Kamrath, L. Wettstaedt, C. Boettcher, M.F. Hartmann, S.A. Wudy, Androgen excess  
532 is due to elevated 11-oxygenated androgens in treated children with congenital adrenal  
533 hyperplasia, The Journal of steroid biochemistry and molecular biology, 178 (2018) 221-228.  
534 [46] K.M. Wooding, R.J. Auchus, Mass spectrometry theory and application to adrenal  
535 diseases, Molecular and cellular endocrinology, 371 (2013) 201-207.  
536

537 **Tables**

538

539 **Table 1: Nomenclature of the 25 steroids analysed in this uPLC-MS/MS assay**

Steroid abbreviation	Trivial name	Chemical name	Functional class
Preg	Pregnenolone	5-pregnene-3 $\beta$ -ol-20-one	General steroid precursor
Prog	Progesterone	4-pregnene-3,20-dione	Progestogen/general steroid precursor
DOC	11-deoxycorticosterone	4-pregnene-21-ol-3,20-dione	Mineralocorticoid precursor
B	Corticosterone	4-pregnene-11 $\beta$ ,21-diol-3,20-dione	Mineralocorticoid precursor
Aldo	Aldosterone	4-pregnene-11 $\beta$ ,21-diol-3,20-dione-18-al	Mineralocorticoid
17Preg	17 $\alpha$ -hydroxypregnenolone	5-pregnene-3 $\beta$ ,17 $\alpha$ -diol-20-one	Glucocorticoid or androgen precursor
17OHP	17 $\alpha$ -hydroxyprogesterone	4-pregnene-17 $\beta$ -ol-3,20-dione	Glucocorticoid precursor
S	11-deoxycortisol	4-pregnene-17 $\alpha$ ,21-diol-3,20-dione	Glucocorticoid precursor
F	Cortisol	4-pregnene-11 $\beta$ ,17 $\alpha$ ,21-triol-3,20-dione	Glucocorticoid
E	Cortisone	4-pregnene-17 $\alpha$ ,21-diol-3,11,20-trione	Glucocorticoid metabolite
DHEA	Dehydroepiandrosterone	5-androstene-3 $\beta$ -ol-17-one	Classic androgen precursor
A4	Androstenedione	4-androstene-3,17-dione	Classic androgen precursor
T	Testosterone	4-androstene-17 $\beta$ -ol-3-one	Classic androgen
DHT	5 $\alpha$ -dihydrotestosterone	5 $\alpha$ -androstane-17 $\beta$ -ol-3-one	Classic androgen
5 $\alpha$ -dione	5 $\alpha$ -androstenedione	5 $\alpha$ -androstane-3,17-dione	Classic androgen metabolite
3 $\alpha$ -adiol	5 $\alpha$ -androstenediol	5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol	Classic androgen metabolite/alternative DHT pathway intermediate



An	5 $\alpha$ -androsterone	5 $\alpha$ -androstane-3 $\alpha$ -ol-17-one	Classic androgen metabolite/alternative DHT pathway intermediate
11KA4	11-ketoandrostenedione	4-androstene-3,11,17-trione	11-oxygenated androgen precursor
11KT	11-ketotestosterone	4-androstene-17 $\beta$ -ol-3,11-dione	11-oxygenated androgen
11OHA4	11 $\beta$ -hydroxyandrostenedione	4-androstene-11 $\beta$ -ol-3,17-dione	11-oxygenated androgen precursor
11OHT	11 $\beta$ -hydroxytestosterone	4-androstene-11 $\beta$ ,17 $\beta$ -diol-3-one	11-oxygenated androgen
5 $\alpha$ DHP	5 $\alpha$ -dihydroprogesterone	5 $\alpha$ -pregnane-3,20-dione	Progestogen metabolite /alternative DHT pathway intermediate
AlloP	Allopregnanolone	5 $\alpha$ -pregnane-3 $\alpha$ -ol-20-one	Progestogen metabolite/alternative DHT pathway intermediate
17OHDHP	17 $\alpha$ -hydroxy-5 $\alpha$ -dihydroprogesterone	5 $\alpha$ -pregnane-17 $\alpha$ -ol-3,20-dione	Progestogen metabolite/alternative DHT pathway intermediate
3 $\alpha$ 5 $\alpha$ 17HP	17 $\alpha$ -hydroxyallopregnanolone (or 5 $\alpha$ ,17 $\alpha$ -hydroxypregnanolone)	5 $\alpha$ -pregnane-3 $\alpha$ ,17 $\alpha$ -diol-20-one	Alternative DHT pathway intermediate

540

541

542 **Table 2: Retention times, quantifier and qualifier mass transitions, collision energies**  
 543 **and cone voltages of target analytes and internal standards.**  
 544

Analyte	Retention time (min)	Mass transition (m/z) Quantifier Qualifier	Cone voltage (V)	Collision energy (eV)
Preg	3.65	299.2 > 281.1	36	12
		317.1 > 281.1	16	14
Prog	3.37	315.1 > 97.1	20	20
		315.1 > 109.1	20	24
DOC	2.21	331.1 > 97.1	26	20
		331.1 > 109.1	26	24
B	1.52	347.2 > 121.1	20	24
		347.2 > 97.1	16	20
Aldo	0.86	361.2 > 343.2	40	16
		361.2 > 315.1	40	18
17Preg	2.42	315.2 > 297.2	8	12
		297.2 > 279.2	4	14
17OHP	2.45	331.1 > 97.1	16	22
		331.1 > 109.1	16	26
S	1.64	347.1 > 109.1	42	26
		347.1 > 97.1	42	22
F	1.06	363.3 > 121.1	42	22
		363.1 > 91.1	42	50
E	0.96	361.1 > 163.1	46	22
		361.1 > 121.01	46	38
DHEA	2.35	271.2 > 253.2	30	10
		289.2 > 253.2	12	8
A4	2.03	287.2 > 109.1	26	22
		287.2 > 97.1	26	22
T	2.26	289.2 > 97.1	40	20
		289.2 > 109.1	40	24
DHT	2.80	291.2 > 255.1	42	14
		291.2 > 159.1	42	22
5 $\alpha$ -dione	2.63	289.2 > 253.1	40	16
		289.2 > 271.1	40	10
3 $\alpha$ -adiol	3.21	275.2 > 257	28	10
		275.2 > 81	28	28
An	3.34	291.2 > 273.2	24	8
		291.2 > 255.2	24	12
11KA4	1.06	301.1 > 121.1	44	22
		301.1 > 257.1	44	22
11KT	1.21	303.1 > 121	20	22
		303.1 > 259.1	20	22
11OHA4	1.34	303.1 > 285.1	30	14
		303.1 > 267.1	30	16
11OHT	1.48	305.2 > 269.2	16	14
		305.2 > 121.1	16	20
5 $\alpha$ DHP	4.01	317.1 > 281.1	38	12
		317.1 > 85.1	24	14
alloP	4.33	319.1 > 301.2	22	8
		319.1 > 283.2	22	14

Internal standard	Retention time (min)	Mass transition (m/z) Quantifier <i>Qualifier</i>	Cone voltage (V)	Collision energy (eV)
17OHDHP	2.95	333.2 > 297.2 315.1 > 111	26 32	14 16
3 $\alpha$ 5 $\alpha$ 17HP	3.85	317.2 > 299.2 317.2 > 111	28 28	12 18
Preg-d2- <sup>13</sup> C2	3.64	321.1 > 303.1	28	8
Prog-d9	3.34	324.2 > 100.1	28	24
DOC-d8	2.18	339.1 > 100.1	26	24
B-d8	1.49	355.1 > 337.2	46	14
Aldo-d8	0.85	369.2 > 351.1	34	16
17Preg-d3	2.4	336.2 > 300.2	12	10
17OHP-d8	2.42	339.1 > 100.1	26	24
S-d2	1.62	349.1 > 97.1	42	22
F-d4	1.06	367.2 > 121.1	28	26
E-d7	0.95	369.1 > 169.1	40	24
DHEA-d6	2.33	277.2 > 219.1	22	14
A4-d7	2.01	294.2 > 109.1	26	22
T-d3	2.25	292.2 > 97.1	46	22
DHT-d3	2.79	294.1 > 258.1	22	16
3 $\alpha$ -adiol-d3	3.20	278.2 > 150.2	20	20
An-d4	3.33	295.1 > 277.2	24	12
11K4-d10	1.04	311 > 265	46	16
11KT-d3	1.20	306.2 > 262.1	20	22
11OHA4-d7	1.30	310.1 > 292.1	30	14
5 $\alpha$ DHP-d4	3.96	323.1 > 305.1	22	8
alloP-d4	4.31	323.1 > 305.1	22	8

545

546

547 **Table 3: Validation summary of matrix effects, recovery and lower limits of**  
 548 **quantification for all steroids.** Matrix effects and recovery were assessed at 5 ng/mL  
 549 (approximately 17 nmol/L) in serum samples from six different donors. The lower limit of  
 550 quantification (LLOQ) was defined as the lowest concentration that can be assessed with  
 551 appropriate accuracy (bias within  $\pm 20\%$ ) and imprecision (CV < 20%).  
 552

Analyte	Matrix effects (%) mean (min-max)	Recovery (%) mean (min-max)	LLOQ (ng/mL)	LLOQ (nmol/L)
Preg	19.9 (-0.4 - 43.8)	93.9 (75.3-110)	0.2	0.6
Prog	7.4 (-8.2 - 19.7)	98.9 (91.3-110)	0.1	0.3
DOC	14.4 (9.1-20.9)	113.6 (102.9-131.4)	0.2	0.5
B	13.5 (5.3-22.5)	91.3 (74.3-110.3)	0.1	0.3
Aldo	12.6 (8.7-17.5)	103.5 (92.4-111.8)	0.2	0.4
17Preg	-15.9 (-57.9-27.8)	105.5 (59.0-129.7)	1.0	3.0
17OHP	-11.4 (-31.3-24.2)	94.5 (78.0-108.6)	0.2	0.6
S	4.3 (-5.0-14.4)	99.9 (88.3-107.9)	0.2	0.4
F	-19.5 (-32.5-16.7)	101.7 (7.5-108.4)	0.1	0.3
E	7.1 (-4.3-19.9)	100.7 (95.7-102.8)	0.1	0.3
DHEA	-1.4 (-20.1-12.9)	105.1 (95.0-118.2)	0.2	0.7
A4	12.7 (0.3-29.0)	95.2 (85.8-112.0)	0.2	0.7
T	0.5 (-8.3-4.9)	102.8 (97.9-106.7)	0.1	0.4
DHT	2.4 (-9.0-10.0)	102.7 (96.6-111.7)	0.1	0.3
5 $\alpha$ -dione	19.2 (7.8-29.7)	104.6 (88.6-113.9)	0.2	0.5
3 $\alpha$ -adiol	4.2 (-44.1-32.8)	109.1 (96.4-138.8)	1.0	3.4
An	13.0 (5.9-23.0)	98.1 (87.0-107)	0.2	0.7
11KA4	-2.6 (-25.4-33.6)	109.0 (77.3-133.9)	0.1	0.3
11KT	10.1 (4.7-16.6)	98.0 (89.3-102.1)	0.1	0.3
11OHA4	-3.6 (-17.4-17.2)	105.9 (94.1-117.8)	0.1	0.3
11OHT	1.7 (-6.7-6.1)	101.8 (96.5-110.2)	0.1	0.3
5 $\alpha$ DHP	-29.9 (-49.9- -8.4)	113.3 (80.9-184.4)	0.2	0.6
alloP	16.0 (-22.3-40.6)	91.6 (74.0-124.1)	0.2	0.6
17OHDHP	-22.6 (-32.7- -3.0)	90.0 (73.5-101.7)	0.5	1.5
3 $\alpha$ 5 $\alpha$ 17HP	-62.7 (-77.2- -45.4)	122.1 (69.2-154.7)	0.5	1.5

553

554

555 **Table 4: Accuracy and intra-assay imprecision determined at four concentrations**  
 556 **spiked into surrogate matrix (n=10).** n/a, not applicable as concentration <LLOQ.

Concentration (ng/mL)	Bias (%)				Imprecision (%)			
	0.3	1	3	30	0.3	1	3	30
Preg	-9.6	-0.4	-1.4	-3.9	8.0	5.4	13.1	4.6
Prog	-6.2	1.6	1.3	-5.0	7.0	5.3	9.1	3.3
DOC	-0.7	-2.0	3.3	-0.2	7.4	7.6	11.6	6.0
B	-5.4	-6.5	-1.8	9.2	9.4	5.8	12.1	4.8
Aldo	-7.7	-2.1	0.1	0.8	7.0	5.1	9.6	5.0
17Preg	n/a	-17	3.8	-3.6	n/a	10.4	16.5	11.1
17OHP	4.9	-0.2	-5.6	0.2	5.7	10.0	9.4	6.2
S	8.4	3.9	6.8	1.8	5.5	4.8	8.3	3.8
F	2.6	7.7	10.3	2.7	5.5	4.9	4.1	2.3
E	0.7	4.7	7.2	5.0	6.7	4.5	8.2	4.3
DHEA	10.6	4.8	0.6	2.3	13.3	10.1	8.0	3.8
A4	6.1	-5.1	-0.4	-4.6	11.3	8.2	6.9	3.7
T	-1.8	5.3	7.5	0.6	7.6	5.6	8.2	3.8
DHT	1.3	6.4	10.2	11.9	6.7	5.1	8.4	3.2
5 $\alpha$ -dione	-2.2	2.0	3.4	-8.0	7.8	9.5	11.2	8.0
3 $\alpha$ -adiol	n/a	4.4	-6.1	2.5	n/a	17.8	11.5	6.5
An	2.5	1.8	-0.5	-2.9	15.2	12.2	9.1	3.5
11KA4	-9.8	-5.7	-0.5	-0.9	8.3	6.1	11.2	5.3
11KT	-8.5	0.5	2.3	-1.6	10.5	4.8	11.6	2.7
11OHA4	-4.1	1.6	2.8	-1.9	6.8	5.7	7.5	3.6
11OHT	0.2	5.6	10.9	4.0	11.6	6.8	8.0	5.0
5 $\alpha$ DHP	-21.0	-8.2	-3.4	-4.6	14.3	12.5	11.6	14.4
alloP	-14.0	-10.7	-14.0	-11.5	20.5	16.1	15.7	15.1
17OHDHP	n/a	4.3	9.1	6.6	n/a	14.7	6.5	11.6
3 $\alpha$ 5 $\alpha$ 17HP	n/a	3.5	7.5	2.0	n/a	9.4	11.0	4.8

557

558

559 **Table 5: Intra- and inter-assay precision of a pooled serum sample and a pooled**  
 560 **serum sample spiked with 5 ng/mL of all analytes. (n=10).** n/a, not applicable as  
 561 concentration below the lower limit of quantification (<LLOQ).

Analyte	Pooled serum			Pooled serum spiked at 5 ng/mL	
	Mean (ng/mL)	Inter-assay CV (%)	Intra-assay CV (%)	Inter-assay CV (%)	Intra-assay CV (%)
Preg	<LLOQ	n/a	n/a	8.2	4.9
Prog	<LLOQ	n/a	n/a	10.8	12.5
DOC	<LLOQ	n/a	n/a	5.9	2.7
B	2.3	11.2	7.3	12.5	3.7
Aldo	<LLOQ	n/a	n/a	5.6	3.7
17Preg	4.8	16.1	16.3	14.7	8.1
17OHP	1.2	5.5	4.2	12.1	4.5
S	0.2	8.1	6.9	5.8	3.5
F	75.2	3.5	2.4	3.7	2.5
E	9.7	4.2	3.4	4.5	3.1
DHEA	2.0	6.5	6.0	6.4	6.1
A4	0.6	15.3	8.0	9.8	9.0
T	4.0	4.7	3.5	3.2	2.3
DHT	0.4	7.5	5.4	5.4	4.1
5 $\alpha$ -dione	<LLOQ	n/a	n/a	12.8	6.1
3 $\alpha$ -adiol	<LLOQ	n/a	n/a	23.0	10.0
An	<LLOQ	n/a	n/a	4.0	2.8
11KA4	0.2	16.0	16.2	8.0	6.0
11KT	0.1	10.1	5.9	4.7	3.0
11OHA4	1.3	12.7	10.2	9.5	5.1
11OHT	0.1	14.9	8.2	5.3	3.2
5 $\alpha$ DHP	<LLOQ	n/a	n/a	22	4.1
alloP	<LLOQ	n/a	n/a	8.1	6.1
17OHDHP	<LLOQ	n/a	n/a	17.2	7.0
3 $\alpha$ 5 $\alpha$ 17HP	<LLOQ	n/a	n/a	23.9	4.2

562

563

564

565

566

567

568

569

570

571

572

573 **Figure legends**

574 **Figure 1: Pathways of adrenal steroidogenesis (A) and androgen biosynthesis (B).**

575 General steroid precursors are shown in yellow, mineralocorticoids in green, glucocorticoids  
576 in orange, androgens in blue. Dark shades of each colour indicate active steroids, light  
577 shades inactive precursors. Abbreviations for steroids included in the uPLC-MS/MS assay  
578 are shown in bold.

579

580 **Figure 2: Ammonium fluoride (NH<sub>4</sub>F) post-column infusion enhances ionisation of**  
581 **steroids in a structure-dependent fashion as compared to mobile phase formic acid.**

582 The percentage increase in peak area of the quantifier transition when comparing post-  
583 column infusion of NH<sub>4</sub>F (6 mmol/L, 5 µL/min) to the use of 0.1% (vol/vol) formic acid in both  
584 the methanol and water mobile phase. Bars represent the mean percentage peak area and  
585 whiskers the relative standard deviation for serum samples from different individuals.  
586 Samples from all individuals with detectable peaks were included (Prog, DOC, B, 17Preg,  
587 17OHP, S, F, E, DHEA, A4, T, DHT, An, 11KA4, 11KT, 11OHA4, 11OHT n=74; Preg n=73;  
588 Aldo n=71; 3α-adiol n=56; 5α-DHP n=48; 17OHDHP n=39; 3α5α17HP n=18; alloP n=15; 5α-  
589 dione n=14). The red line indicates a relative peak area of 100% (identical ionisation with  
590 both methods). The colour of the bars indicates the functional class of each analyte; yellow,  
591 general steroid precursor; light green, mineralocorticoid precursor; dark green,  
592 mineralocorticoid; orange, glucocorticoid precursor; red, glucocorticoid; turquoise, androgen  
593 precursor; dark blue, androgen; light blue, alternative DHT biosynthesis pathway  
594 intermediate.

595

596 **Figure 3: Human Serum Steroid Profiles.** Serum steroid profiles in healthy volunteers,  
597 female (red circles; n=10, age range 20-40 years) and male (blue circles, n=10, age range  
598 30-40 years). Each symbol represents one participant; values <LLOQ are represented by  
599 open circles and undetectable levels were not included in the visualisation. 17OHDHP was  
600 undetectable in any of the samples.


601

602

603

604

605

**A****B**